These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

509 related items for PubMed ID: 19483091

  • 1. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis.
    Horneff G, Ebert A, Fitter S, Minden K, Foeldvari I, Kümmerle-Deschner J, Thon A, Girschick HJ, Weller F, Huppertz HI.
    Rheumatology (Oxford); 2009 Aug; 48(8):916-9. PubMed ID: 19483091
    [Abstract] [Full Text] [Related]

  • 2. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.
    Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore JB, White B, Giannini EH, Pediatric Rheumatology Collaborative Study Group.
    Arthritis Rheum; 2006 Jun; 54(6):1987-94. PubMed ID: 16732547
    [Abstract] [Full Text] [Related]

  • 3. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.
    Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK.
    N Engl J Med; 2000 Mar 16; 342(11):763-9. PubMed ID: 10717011
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
    Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H, German and Austrian Paediatric Rheumatology Collaborative Study Group.
    Ann Rheum Dis; 2009 Apr 16; 68(4):519-25. PubMed ID: 18413440
    [Abstract] [Full Text] [Related]

  • 5. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, Burge DJ.
    Arthritis Rheum; 2004 Feb 16; 50(2):353-63. PubMed ID: 14872476
    [Abstract] [Full Text] [Related]

  • 6. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial.
    Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Lange M, Finck BK, Burge DJ, Pediatric Rheumatology Collaborative Study Group.
    Arthritis Rheum; 2003 Jan 16; 48(1):218-26. PubMed ID: 12528122
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
    Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, Sibilia J, Koné-Paut I, Gandon-Laloum S, LeBideau M, Bader-Meunier B, Mouy R, Debré M, Landais P, Prieur AM.
    Arthritis Rheum; 2003 Apr 16; 48(4):1093-101. PubMed ID: 12687553
    [Abstract] [Full Text] [Related]

  • 8. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
    Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, van Santen-Hoeufft M, Koopman-Keemink Y, Wulffraat NM, van Suijlekom-Smit LW.
    Ann Rheum Dis; 2009 May 16; 68(5):635-41. PubMed ID: 18413443
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study.
    Weinblatt ME, Schiff MH, Ruderman EM, Bingham CO, Li J, Louie J, Furst DE.
    Arthritis Rheum; 2008 Jul 16; 58(7):1921-30. PubMed ID: 18576334
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.
    Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, Baumgartner SW, Giannini EH, Pediatric Rheumatology Collaborative Study Group.
    Arthritis Rheum; 2008 May 16; 58(5):1496-504. PubMed ID: 18438876
    [Abstract] [Full Text] [Related]

  • 11. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.
    Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, Robinson M, Kim J, Barron KS.
    Arthritis Rheum; 2005 Feb 15; 53(1):18-23. PubMed ID: 15696578
    [Abstract] [Full Text] [Related]

  • 12. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V, Pontikaki I, Gattinara M, Fantini F.
    Ann Rheum Dis; 2008 Aug 15; 67(8):1145-52. PubMed ID: 17981916
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis.
    Takei S, Groh D, Bernstein B, Shaham B, Gallagher K, Reiff A.
    J Rheumatol; 2001 Jul 15; 28(7):1677-80. PubMed ID: 11469478
    [Abstract] [Full Text] [Related]

  • 14. Prolonged efficacy of etanercept in refractory enthesitis-related arthritis.
    Henrickson M, Reiff A.
    J Rheumatol; 2004 Oct 15; 31(10):2055-61. PubMed ID: 15468375
    [Abstract] [Full Text] [Related]

  • 15. The German etanercept registry for treatment of juvenile idiopathic arthritis.
    Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, Hospach T, Huppertz HI, Keitzer R, Küster RM, Michels H, Moebius D, Rogalski B, Thon A, Paediatric Rheumatology Collaborative Group.
    Ann Rheum Dis; 2004 Dec 15; 63(12):1638-44. PubMed ID: 15115709
    [Abstract] [Full Text] [Related]

  • 16. Etanercept therapy in children with treatment-resistant uveitis.
    Reiff A, Takei S, Sadeghi S, Stout A, Shaham B, Bernstein B, Gallagher K, Stout T.
    Arthritis Rheum; 2001 Jun 15; 44(6):1411-5. PubMed ID: 11407702
    [Abstract] [Full Text] [Related]

  • 17. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein.
    Zhou H.
    J Clin Pharmacol; 2005 May 15; 45(5):490-7. PubMed ID: 15831771
    [Abstract] [Full Text] [Related]

  • 18. [Efficacy of etanercept in the treatment of juvenile idiopathic arthritis].
    de Inocencio Arocena J, Merino Muñoz R, Alvarez Madrid C, García-Consuegra Molina J.
    An Pediatr (Barc); 2009 Apr 15; 70(4):354-61. PubMed ID: 19324597
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study.
    Gerloni V, Pontikaki I, Gattinara M, Desiati F, Lupi E, Lurati A, Salmaso A, Fantini F.
    Arthritis Rheum; 2005 Feb 15; 52(2):548-53. PubMed ID: 15693004
    [Abstract] [Full Text] [Related]

  • 20. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis.
    Papsdorf V, Horneff G.
    Rheumatology (Oxford); 2011 Jan 15; 50(1):214-21. PubMed ID: 21148155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.